Seegene, Stock Price -1.14% at This Time... Institutional Investors Net Buy 87,295 Shares in Last 5 Days
As of 9:30 AM on the 21st, Seegene is trading at 261,000 KRW, down 1.14% from the previous day. The trading volume is 133,600 shares, which is about 17.84% of the previous day's volume. Seegene is known as a company that develops, manufactures, and sells molecular diagnostic reagents.
On September 18, Yoon Chang-min, a researcher at Shinhan Financial Investment, stated, "Compared to the early spread of COVID-19, the supply and demand of diagnostic kits have entered a stabilization phase. Seegene has competitiveness in all areas including technology, distribution channels, and production capacity compared to other companies. Unlike other companies with high earnings volatility, it maintains steady earnings growth, showing differentiation." He set Seegene's target price at 350,000 KRW.
Over the past five days, individual investors have net sold 45,330 shares of Seegene, while foreigners and institutions have net sold 27 shares and net bought 87,295 shares, respectively.
Hot Picks Today
"How Much Will They Get?" 600 Million vs. 460 Million vs. 160 Million... Samsung Electronics DS Division's 'Three Wallets Under One Roof'
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- Samsung Electronics Labor and Management Reach Dramatic Agreement on Eve of Strike After 6 Months; 10.5% of Semiconductor Performance to Be Distributed
- Room Prices Soar from 60,000 to 760,000 Won and Sudden Cancellations: "We Won't Even Buy Water in Busan" — BTS Fans Outraged
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?

※Source: AI Investment Assistant AI Rassiro
※ This article was generated in real-time by an article auto-generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.